Overview

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Collaborator:
Vertex Pharmaceuticals Incorporated
Criteria
Inclusion Criteria:

- Patients diagnosed with genotype 1b chronic hepatitis C

- Patients naive to the concomitant medications with interferon

Exclusion Criteria:

- Patients diagnosed with decompensated cirrhosis

- Patients diagnosed with positive HBs(Hepatitis B virus surface) antigen in the test